Strongyloidiasis Antibodies Found in Transplant Donors
By LabMedica International staff writers Posted on 10 Dec 2018 |

Image: A histopathology of Strongyloides stercoralis in the duodenum (Photo courtesy of Dr. Raul S. Gonzalez, MD).
Strongyloidiasis is a neglected tropical disease caused by a parasite, which is endemic in most parts of the world. It can cause a life-threatening disease among immunosuppressed individuals and can be transmitted from solid organ transplant (SOT) donors to recipients.
Due to the characteristic life cycle of Strongyloides stercoralis, individuals can carry the infection lifelong with mild or no symptoms, unless treated. The disease endemic in large parts of Latin America, Asia and Africa with an estimated prevalence of more than 400 million infected.
Scientists at the Universitat de Barcelona (Barcelona, Spain) carried out a retrospective study including all deceased individuals from endemic areas for strongyloidiasis who were considered for organ donation between January 2004 and December 2014 in the Hospital Clinic. During the period 2004–2014, 1,025 deceased individuals were evaluated as potential deceased organ donors. Of these, 90 donors (8.78%) were native from endemic areas for strongyloidiasis. Most were males (63/90 cases; 70%) and median age of all cases was 41 years old. More than half of the deceased organ donors from endemic areas had been born in Latin America (49/90 cases; 54.44%), whereas the rest were from Southeast Asia (24/90 cases; 26.67%) and Africa (17/90 cases; 18.89%).
The team used the serum samples of potential donors from endemic areas for strongyloidiasis, and performed a S. stercoralis serological test. The commercial test IVD-ELISA, which detects immunoglobulin G (IgG) antibodies by using somatic antigens from larvae of the parasite, was used and has a sensitivity of 91.2%, and a specificity of 99.1%. Currently, IVD-ELISA is the available test in the hospital. The sample is defined as positive if the absorbance/0.2 (i) > 1.1.
The scientists found there were only in 65 of 90 cases available serum samples and analyzed for S. stercoralis serology and 6/65 cases (9.23%) were found to have a positive test for strongyloidiasis. S. stercoralis serology indices ranged between 1.84 and 9.32. From the six positive cases, three individuals were native from Latin America (two from Brazil and one from Ecuador), two from Africa (Senegal and Ghana) and one from Southeast Asia (Philippines).
The authors concluded that they had found a high seroprevalence of strongyloidiasis in individuals from endemic settings evaluated as potential deceased donors for SOT. The data reinforce the importance of following current guidelines recommending systematic screening of potential donors from endemic areas. There is an urgent need to develop rapid diagnostic tests, which can be used in daily clinical practice. The study was published on November 29, 2018, in the journal Public Library of Science Neglected tropical Diseases.
Related Links:
Universitat de Barcelona
Due to the characteristic life cycle of Strongyloides stercoralis, individuals can carry the infection lifelong with mild or no symptoms, unless treated. The disease endemic in large parts of Latin America, Asia and Africa with an estimated prevalence of more than 400 million infected.
Scientists at the Universitat de Barcelona (Barcelona, Spain) carried out a retrospective study including all deceased individuals from endemic areas for strongyloidiasis who were considered for organ donation between January 2004 and December 2014 in the Hospital Clinic. During the period 2004–2014, 1,025 deceased individuals were evaluated as potential deceased organ donors. Of these, 90 donors (8.78%) were native from endemic areas for strongyloidiasis. Most were males (63/90 cases; 70%) and median age of all cases was 41 years old. More than half of the deceased organ donors from endemic areas had been born in Latin America (49/90 cases; 54.44%), whereas the rest were from Southeast Asia (24/90 cases; 26.67%) and Africa (17/90 cases; 18.89%).
The team used the serum samples of potential donors from endemic areas for strongyloidiasis, and performed a S. stercoralis serological test. The commercial test IVD-ELISA, which detects immunoglobulin G (IgG) antibodies by using somatic antigens from larvae of the parasite, was used and has a sensitivity of 91.2%, and a specificity of 99.1%. Currently, IVD-ELISA is the available test in the hospital. The sample is defined as positive if the absorbance/0.2 (i) > 1.1.
The scientists found there were only in 65 of 90 cases available serum samples and analyzed for S. stercoralis serology and 6/65 cases (9.23%) were found to have a positive test for strongyloidiasis. S. stercoralis serology indices ranged between 1.84 and 9.32. From the six positive cases, three individuals were native from Latin America (two from Brazil and one from Ecuador), two from Africa (Senegal and Ghana) and one from Southeast Asia (Philippines).
The authors concluded that they had found a high seroprevalence of strongyloidiasis in individuals from endemic settings evaluated as potential deceased donors for SOT. The data reinforce the importance of following current guidelines recommending systematic screening of potential donors from endemic areas. There is an urgent need to develop rapid diagnostic tests, which can be used in daily clinical practice. The study was published on November 29, 2018, in the journal Public Library of Science Neglected tropical Diseases.
Related Links:
Universitat de Barcelona
Latest Microbiology News
- Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
- Innovative ID/AST System to Help Diagnose Infectious Diseases and Combat AMR
- Gastrointestinal Panel Delivers Rapid Detection of Five Common Bacterial Pathogens for Outpatient Use
- Rapid PCR Testing in ICU Improves Antibiotic Stewardship
- Unique Genetic Signature Predicts Drug Resistance in Bacteria
- Unique Barcoding System Tracks Pneumonia-Causing Bacteria as They Infect Blood Stream
- Rapid Sepsis Diagnostic Test Demonstrates Improved Patient Care and Cost Savings in Hospital Application
- Rapid Diagnostic System to Detect Neonatal Sepsis Within Hours
- Novel Test to Diagnose Bacterial Pneumonia Directly from Whole Blood
- Interferon-γ Release Assay Effective in Patients with COPD Complicated with Pulmonary Tuberculosis
- New Point of Care Tests to Help Reduce Overuse of Antibiotics
- 30-Minute Sepsis Test Differentiates Bacterial Infections, Viral Infections, and Noninfectious Disease
- CRISPR-TB Blood Test to Enable Early Disease Diagnosis and Public Screening
- Syndromic Panel Provides Fast Answers for Outpatient Diagnosis of Gastrointestinal Conditions
- Culture-Free Platform Rapidly Identifies Blood Stream Infections
- POC PCR Test Rapidly Detects Bacterial Meningitis Directly at Point of Sample Collection
Channels
Clinical Chemistry
view channel
Carbon Nanotubes Help Build Highly Accurate Sensors for Continuous Health Monitoring
Current sensors can measure various health indicators, such as blood glucose levels, in the body. However, there is a need to develop more accurate and sensitive sensor materials that can detect lower... Read more
Paper-Based Device Boosts HIV Test Accuracy from Dried Blood Samples
In regions where access to clinics for routine blood tests presents financial and logistical obstacles, HIV patients are increasingly able to collect and send a drop of blood using paper-based devices... Read moreMolecular Diagnostics
view channel
D-Dimer Testing Can Identify Patients at Higher Risk of Pulmonary Embolism
Pulmonary embolism (PE) is a commonly suspected condition in emergency departments (EDs) and can be life-threatening if not diagnosed correctly. Achieving an accurate diagnosis is vital for providing effective... Read more
New Biomarkers to Improve Early Detection and Monitoring of Kidney Injury
Drug-induced kidney injury, also known as nephrotoxicity, is a prevalent issue in clinical practice, occurring when specific medications at certain doses cause damage to the kidneys. Nephrotoxicity can... Read moreHematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read moreImmunology
view channel
Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions
In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read moreCerebrospinal Fluid Test Predicts Dangerous Side Effect of Cancer Treatment
In recent years, cancer immunotherapy has emerged as a promising approach where the patient's immune system is harnessed to fight cancer. One form of immunotherapy, called CAR-T-cell therapy, involves... Read more
New Test Measures Preterm Infant Immunity Using Only Two Drops of Blood
Preterm infants are particularly vulnerable due to their organs still undergoing development, which can lead to difficulties in breathing, eating, and regulating body temperature. This is especially true... Read more
Simple Blood Test Could Help Choose Better Treatments for Patients with Recurrent Endometrial Cancer
Endometrial cancer, which develops in the lining of the uterus, is the most prevalent gynecologic cancer in the United States, affecting over 66,000 women annually. Projections indicate that in 2025, around... Read morePathology
view channel
AI Model Predicts Patient Response to Bladder Cancer Treatment
Each year in the United States, around 81,000 new cases of bladder cancer are diagnosed, leading to approximately 17,000 deaths annually. Muscle-invasive bladder cancer (MIBC) is a severe form of bladder... Read more
New Laser-Based Method to Accelerate Cancer Diagnosis
Researchers have developed a method to improve cancer diagnostics and other diseases. Collagen, a key structural protein, plays various roles in cell activity. A novel multidisciplinary study published... Read more
New AI Model Predicts Gene Variants’ Effects on Specific Diseases
In recent years, artificial intelligence (AI) has greatly enhanced our ability to identify a vast number of genetic variants in increasingly larger populations. However, up to half of these variants are... Read more
Powerful AI Tool Diagnoses Coeliac Disease from Biopsy Images with Over 97% Accuracy
Coeliac disease is an autoimmune disorder triggered by the consumption of gluten, causing symptoms such as stomach cramps, diarrhea, skin rashes, weight loss, fatigue, and anemia. Due to the wide variation... Read moreTechnology
view channel
Smartphones Could Diagnose Diseases Using Infrared Scans
Rapid advancements in technology may soon make it possible for individuals to bypass invasive medical procedures by simply uploading a screenshot of their lab results from their phone directly to their doctor.... Read more
Novel Sensor Technology to Enable Early Diagnoses of Metabolic and Cardiovascular Disorders
Metabolites are critical compounds that fuel life's essential functions, playing a key role in producing energy, regulating cellular activities, and maintaining the balance of bodily systems.... Read more
3D Printing Breakthrough Enables Large Scale Development of Tiny Microfluidic Devices
Microfluidic devices are diagnostic systems capable of analyzing small volumes of materials with precision and speed. These devices are used in a variety of applications, including cancer cell analysis,... Read moreIndustry
view channel
Tecan Acquires ELISA Immunoassay Assets from Revvity's Cisbio Bioassays
Tecan Group (Männedorf, Switzerland) has entered into an agreement to acquire certain assets relating to key ELISA immunoassay products from Cisbio Bioassays SAS (Codolet, France), a subsidiary of the... Read more